ARCHIVES

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

This article is from The Cancer Letter archive.

Vol. 05 No. 35 | August 31, 1979

Download PDF Visit The Full Archive

Related Articles

NKTR-102 Shows 29 Percent Response in Phase II Study

September 30, 2011

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

October 25, 2013

Nutrition Research Tests Hypotheses, Seeks Explanation Of Differences

August 14, 1981

Caplan: NEJM Should Go “The Extra Moral Mile”

January 9, 2009

In Brief: PHS Established Two Scientific Integrity Offices; Workshop On Ethical Issues Planned

August 18, 1989

Letter: Cancer Centers Need Ingenuity To Continue Clinical Research

October 27, 1995